Investor Relations
Investor Relations Contact:
LHA
Anne Marie Fields
212-838-3777
afields@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com

Media Contact
Rooney & Associates
Terry Rooney
212-223-0689
trooney@rooneyco.com
or
Marion Janic
212-223-4017
mjanic@rooneyco.com

Press Releases

All Releases
View Summary OPKO Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Aug 30, 2007
PDF 11.4 KB
View Summary OPKO Health, Inc. Announces Early Termination of Hart-Scott-Rodino Period for Proposed Purchase of Shares by Dr. Phillip Frost
Jul 12, 2007
PDF 7.4 KB
View Summary OPKO Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD
Jul 11, 2007
PDF 10.4 KB
View Summary Exegenics Changes Name to OPKO Health and Receives Approval for Its Shares to Trade on the American Stock Exchange Under the Symbol OPK
Jun 8, 2007
PDF 4.1 KB
View Summary OPKO Health, Inc. to Acquire Diagnostic Imaging Firm
Jun 1, 2007
PDF 6.4 KB
View Summary Exegenics, Inc. Announces Senior Management Appointments; Company Intends to Change its Name to OPKO Health
May 4, 2007
PDF 9.2 KB
View Summary Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
Mar 27, 2007
PDF 11.0 KB
Showing 321-327 of 327 Page: 1 ... 13 14 15 16 17  Previous 20

Email  Sign up for email alerts